Pictet Asset Management Ltd. boosted its position in C R Bard Inc (NYSE:BCR) by 27.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,492 shares of the medical instruments supplier’s stock after buying an additional 10,590 shares during the period. Pictet Asset Management Ltd. owned approximately 0.07% of C R Bard worth $12,052,000 as of its most recent filing with the SEC.
Other institutional investors have also recently added to or reduced their stakes in the company. Xact Kapitalforvaltning AB increased its position in C R Bard by 62.6% in the first quarter. Xact Kapitalforvaltning AB now owns 7,755 shares of the medical instruments supplier’s stock worth $1,927,000 after buying an additional 2,986 shares during the period. Trust Co. of Vermont increased its position in C R Bard by 5.9% in the first quarter. Trust Co. of Vermont now owns 5,606 shares of the medical instruments supplier’s stock worth $1,393,000 after buying an additional 312 shares during the period. BNP Paribas Arbitrage SA increased its position in C R Bard by 201.7% in the first quarter. BNP Paribas Arbitrage SA now owns 70,804 shares of the medical instruments supplier’s stock worth $17,598,000 after buying an additional 47,332 shares during the period. Buffington Mohr McNeal increased its position in C R Bard by 14.1% in the first quarter. Buffington Mohr McNeal now owns 7,545 shares of the medical instruments supplier’s stock worth $1,875,000 after buying an additional 930 shares during the period. Finally, Princeton Alpha Management LP purchased a new position in C R Bard during the first quarter worth $407,000. 86.89% of the stock is owned by hedge funds and other institutional investors.
C R Bard Inc (NYSE:BCR) traded up 0.39% on Friday, reaching $307.58. The company’s stock had a trading volume of 348,890 shares. The firm has a market cap of $22.27 billion, a price-to-earnings ratio of 39.15 and a beta of 0.63. C R Bard Inc has a 12 month low of $203.63 and a 12 month high of $309.16. The firm has a 50 day moving average of $280.57 and a 200 day moving average of $243.25.
C R Bard (NYSE:BCR) last posted its quarterly earnings data on Sunday, April 23rd. The medical instruments supplier reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.22. C R Bard had a return on equity of 48.48% and a net margin of 14.31%. The firm had revenue of $938.80 million during the quarter, compared to analysts’ expectations of $916.15 million. During the same period in the prior year, the business earned $2.34 EPS. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. Analysts anticipate that C R Bard Inc will post $11.78 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, May 12th. Stockholders of record on Monday, May 1st were issued a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.34%. The ex-dividend date was Thursday, April 27th. C R Bard’s payout ratio is currently 14.77%.
WARNING: This report was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.themarketsdaily.com/2017/05/19/pictet-asset-management-ltd-purchases-10590-shares-of-c-r-bard-inc-bcr.html.
Several equities research analysts have recently commented on BCR shares. Zacks Investment Research downgraded C R Bard from a “buy” rating to a “hold” rating in a report on Friday, May 12th. Raymond James Financial, Inc. downgraded C R Bard from a “strong-buy” rating to a “mkt perform” rating in a report on Wednesday, April 26th. Wells Fargo & Co downgraded C R Bard from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 25th. BMO Capital Markets downgraded C R Bard from an “outperform” rating to a “market perform” rating and set a $245.00 price objective for the company. in a report on Tuesday, April 25th. Finally, Morgan Stanley downgraded C R Bard from an “overweight” rating to an “equal weight” rating in a report on Monday, April 24th. Twelve analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $263.21.
In related news, insider Jim C. Beasley sold 4,390 shares of the stock in a transaction dated Tuesday, February 21st. The stock was sold at an average price of $245.00, for a total transaction of $1,075,550.00. Following the completion of the sale, the insider now directly owns 26,625 shares in the company, valued at approximately $6,523,125. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Frank Lupisella, Jr. sold 3,622 shares of the stock in a transaction dated Monday, April 24th. The shares were sold at an average price of $304.00, for a total value of $1,101,088.00. Following the sale, the vice president now owns 10,139 shares of the company’s stock, valued at $3,082,256. The disclosure for this sale can be found here. 0.97% of the stock is currently owned by corporate insiders.
C R Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C R Bard Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard Inc and related companies with MarketBeat.com's FREE daily email newsletter.